Metabolic dysfunction-associated steatotic liver disease (MASLD) plays a pivotal role in cardiometabolic health, driven by its bidrectional relationship with cardiovascular disease (CVD) and its impact on long-term morbidity and mortality. This interdisciplinary vodcast explores the shared pathophysiologic pathways connecting MASLD and CVD and underscores the importance of comprehensive risk evaluation. A panel of experts discusses practical, evidence-based strategies for managing MASLD, including lifestyle interventions and the evolving landscape of pharmacologic therapies. The program highlights emerging cardiometabolic agents, including GLP 1-based therapies, ande their potential to slow disease progression and reduce cardiovascular risk in affected patients.